Defining the clinical course of multiple sclerosisFred Lublin, Chris H. Polman, Stephen C. Reingold et al.|Neurology|2014Cited by 3.1k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|Multiple Sclerosis Journal|2018Cited by 706
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialGıancarlo Comı, Massimo Filippi, Vittorio Martinelli et al.|The Lancet|2009Cited by 587
Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelinesMassimo Filippi, Maria A. Rocca, Paolo Preziosa et al.|Brain|2019Cited by 554
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, Ludwig Kappos, David H. Miller et al.|The Lancet|2016Cited by 449